|Dr. Maria L. MacCecchini Ph.D.||Founder, CEO, Pres & Director||420k||N/A||1951|
|Mr. Jeffrey B. McGroarty CPA||Chief Financial Officer||300k||N/A||1969|
|Dr. Jeffrey L. Cummings||Chief Medical Advisor & Member of Scientific Advisory Board||N/A||N/A||1950|
|Dr. William C. Mobley||Chief Scientific Advisor & Member of Scientific Advisory Board||N/A||N/A||N/A|
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Annovis Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.